annb0t
Top 20
Opthea Limited
MELBOURNE, Australia, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that the Phase 2b study results of OPT-302, the Companyâs anti-VEGF-C/-D âtrapâ agent administered in combination with Lucentis® (ranibizumab) for the treatment of wet age-related macular degeneration (AMD), have been publishe...
>>> Read more: Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology
MELBOURNE, Australia, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that the Phase 2b study results of OPT-302, the Companyâs anti-VEGF-C/-D âtrapâ agent administered in combination with Lucentis® (ranibizumab) for the treatment of wet age-related macular degeneration (AMD), have been publishe...
>>> Read more: Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology
